Referência de medicamentos
Zanidatamab
Zanidatamab is a medicine in the class oncology. It is used for biliary tract cancers.
- Classe do medicamento: Oncology
- Indicado para: biliary tract cancers
Última atualização Fontes: US FDA label, EMA SmPC
Para profissionais de saúde — apenas referência. Esta página é um resumo breve, não é aconselhamento médico nem substitui a bula oficial ou o julgamento clínico. Verifique sempre antes de prescrever ou dispensar.
O conteúdo clínico desta página está disponível apenas em inglês.
Pontos-chave
- Classe do medicamento
- Oncology
- Código ATC
- L01FD07
- Formas farmacêuticas comuns
- injeção
- Concentrações comuns
- 50 mg/ml
- Interações conhecidas
- 1 (Moderada: 1)
- Nomes comerciais
- 2
- Países e mercados
- 2
Para que é usado
Como funciona
Bispecific HER2-directed antibody binding extracellular domains 2 and 4 of HER2, causing clustering, internalization and receptor reduction; induces CDC, ADCC and ADCP, leading to tumor growth inhibition and cell death.
Dose habitual em adultos (resumo da bula)
GEA, patients <70 kg: 1,800 mg IV every 3 weeks or 1,200 mg every 2 weeks with fluoropyrimidine- and platinum-containing chemotherapy, with or without tislelizumab-jsgr; until disease progression or unacceptable toxicity
Gravidez e amamentação
- Gravidez
- Unsafe Can cause fetal harm; not recommended during pregnancy. HER2-directed antibodies have caused oligohydramnios, pulmonary hypoplasia, skeletal abnormalities and neonatal death.
- Amamentação
- Unknown No data on presence in human milk or effects on infant. Weigh benefits of breastfeeding against clinical need; consider half-life of about 24 days and 4-month washout.
Efeitos adversos relatados
- Diarrhea
- Nausea
- Decreased appetite
- Vomiting
- Hypokalemia
- Fatigue
Advertências de caixa preta
- With fluoropyrimidine- and platinum-containing chemotherapy, with or without tislelizumab-jsgr, can cause severe diarrhea, including life-threatening and fatal cases. Use antidiarrheal prophylaxis in the first cycle; interrupt, reduce dose or discontinue based on severity. Exposure during pregnancy can cause embryo-fetal harm; advise of risk and need for effective contraception.
Quem deve ter cuidado
- Severe, life-threatening and fatal diarrhea can occur despite loperamide prophylaxis; higher risk with tislelizumab and in patients aged 65 years or older.
- Left ventricular dysfunction: assess LVEF before starting and at regular intervals; safety not established with baseline LVEF below 50%.
- Infusion-related reactions: premedicate, monitor, slow or stop infusion; permanently discontinue for recurrent severe or life-threatening IRRs.
Informe ao farmacêutico ou ao médico sobre gravidez ou amamentação, doença renal ou hepática, alergias e todos os outros medicamentos ou suplementos que você usa.
Principais interações (1)
- Fluorouracil + Zanidatamab Moderate
Para assinantes do Pro+
Desbloqueie a página completa
Crie uma conta e comece um teste do Pro+ para abrir a monografia completa de Zanidatamab: doses, gravidez e amamentação, efeitos adversos, advertências e todas as interações.
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Dosing in older adults
- How to give it
- Pharmacokinetics
- Patient counselling points
Experimente o Pro+ grátis por 14 dias na web. Sem cartão.
Outros medicamentos desta classe
Perguntas frequentes
What is Zanidatamab used for?
Zanidatamab is a medicine in the class oncology. It is used for Biliary tract cancers, Gastric cancer.
What side effects have been reported with Zanidatamab?
Diarrhea, Nausea, Decreased appetite, Vomiting, Hypokalemia, Fatigue. Serious warning: With fluoropyrimidine- and platinum-containing chemotherapy, with or without tislelizumab-jsgr, can cause severe diarrhea, including life-threatening and fatal cases.
Can Zanidatamab be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm; not recommended during pregnancy. HER2-directed antibodies have caused oligohydramnios, pulmonary hypoplasia, skeletal abnormalities and neonatal death. Breastfeeding: Unknown. No data on presence in human milk or effects on infant. Weigh benefits of breastfeeding against clinical need; consider half-life of about 24 days and 4-month washout.
What does Zanidatamab interact with?
MediHelp lists 1 known interactions for Zanidatamab. Moderate: 1. The most serious include Fluorouracil.
Monografias completas, posologia e verificador de interações no app MediHelp
Abra a referência completa, verifique interações entre vários medicamentos e use as ferramentas de posologia no app MediHelp.
